Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource
Language
Englisch

Bibliographic citation
In: European journal of haematology, 114, 1, S. 17-25

Event
Veröffentlichung
(where)
Bochum
(who)
Ruhr-Universität Bochum
(when)
2024
Creator
Wille, Kai
Dumke, Marvin
Wilsdorf, Nadine
Sadjadian, Parvis
Schneider, Artur
Jender-Bartling, Stephanie
Kolatzki, Vera
Horstmann, Anette
Meixner, Raphael
Jiménez-Muñoz, Marina
Fuchs, Christiane
Tischler, Hans-Joachim
Griesshammer, Martin

URN
urn:nbn:de:hbz:294-114969
Rights
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:30 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Wille, Kai
  • Dumke, Marvin
  • Wilsdorf, Nadine
  • Sadjadian, Parvis
  • Schneider, Artur
  • Jender-Bartling, Stephanie
  • Kolatzki, Vera
  • Horstmann, Anette
  • Meixner, Raphael
  • Jiménez-Muñoz, Marina
  • Fuchs, Christiane
  • Tischler, Hans-Joachim
  • Griesshammer, Martin
  • Ruhr-Universität Bochum

Time of origin

  • 2024

Other Objects (12)

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia

Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy

Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy

Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy

Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting

Efficacy and safety of venetoclax combination therapy for relapsed/refractory acute myeloid leukemia: a systematic review and meta-analysis

Efficacy and safety of venetoclax combination therapy for relapsed/refractory acute myeloid leukemia: a systematic review and meta-analysis

Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study

Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)

Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis

Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis

Venetoclax-based therapies in pediatric advanced MDS and relapsed/refractory AML: a multicenter retrospective analysis

Venetoclax-based therapies in pediatric advanced MDS and relapsed/refractory AML: a multicenter retrospective analysis

Related objects